Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
Leqembi is a Aβ monoclonal antibody that preferentially binds to toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates).
Hosted on MSN2mon
The Complex Pathogenesis and Genetics of Alzheimer's DiseaseRecent successes with anti-amyloid monoclonal antibodies in treating early ... and molecular processes likely play a role as well, as Aβ may also lead to cognitive impairment via synapse damage ...
Background High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug ...
Eisai Inc. announced today that the company will present the latest findings from its robust neurology portfolio, including data on real-world experience and continued maintenance dosing with our dual ...
CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback